Acetylcholinesterase (AChE) is the key enzyme responsible for deactivating the ACh neurotransmitter. Irreversible or prolonged inhibition of AChE, therefore, elevates synaptic ACh leading to serious central and peripheral adverse effects which fall under the cholinergic syndrome spectra. To combat the toxic effects of some AChEI, such as organophosphorus (OP) nerve agents, many compounds with reactivator effects have been developed. Within the most outstanding reactivators, the substances denominated oximes stand out, showing good performance for reactivating AChE and restoring the normal synaptic acetylcholine (ACh) levels. This review was developed with the purpose of covering the new advances in AChE reactivation. Over the past years, researchers worldwide have made efforts to identify and develop novel active molecules. These researches have been moving farther into the search for novel agents that possess better effectiveness of reactivation and broad-spectrum reactivation against diverse OP agents. In addition, the discovery of ways to restore AChE in the aged form is also of great importance. This review will allow us to evaluate the major advances made in the discovery of new acetylcholinesterase reactivators by reviewing all patents published between 2016 and 2019. This is an important step in continuing this remarkable research so that new studies can begin.

Department of Chemistry Faculty of Science University of Hradec Kralove 500 03 Hradec Kralove Czech Republic

Department of Chemistry Federal University of Lavras Lavras 37200 000 Brazil

Zobrazit více v PubMed

Ganesan K., Raza S., Vijayaraghavan R. Chemical warfare agents. J. Pharm. Bioallied Sci. 2010;2:166–178. doi: 10.4103/0975-7406.68498. PubMed DOI PMC

El-Ebiary A.A., Elsharkawy R.E., Soliman N.A., Soliman M.A., Hashem A.A. N -acetylcysteine in Acute Organophosphorus Pesticide Poisoning: A Randomized, Clinical Trial. Basic Clin. Pharmacol. Toxicol. 2016;119:222–227. doi: 10.1111/bcpt.12554. PubMed DOI

Black R.M., Read R.W. Biological markers of exposure to organophosphorus nerve agents. Arch. Toxicol. 2013;87:421–437. doi: 10.1007/s00204-012-1005-1. PubMed DOI

Dong H., Weng Y.B., Zhen G.S., Li F.J., Jin A.C., Liu J., Pany S. Clinical emergency treatment of 68 critical patients with severe organophosphorus poisoning and prognosis analysis after rescue. Medicine. 2017;96:9–12. doi: 10.1097/MD.0000000000007237. PubMed DOI PMC

Kassa J., Korabecny J., Nepovimova E., Jun D. The influence of modulators of acetylcholinesterase on the resistance of mice against soman and on the effectiveness of antidotal treatment of soman poisoning in mice. J. Appl. Biomed. 2018;16:10–14. doi: 10.1016/j.jab.2017.01.004. DOI

Terekhov S.S., Palikov V.A., Palikova Y.A., Dyachenko I.A., Shamborant O.G., Smirnov I.V., Masson P., Gabibov A.G. Application of Tetrameric Recombinant Human Butyrylcholinesterase as a Biopharmaceutical for Amelioration of Symptoms of Acute Organophosphate Poisoning. Bull. Exp. Biol. Med. 2017;163:430–435. doi: 10.1007/s10517-017-3821-z. PubMed DOI

Ranjith K.G.K., Nagabhushana S., Ranganatha M., Virupakshappa K. Clinical Pattern and Outcome of Organophosphorus Compound Poisoning. J. Evol. Med. Dent. Sci. 2016;5:3030–3033.

Masson P., Nachon F. Cholinesterase reactivators and bioscavengers for pre- and post-exposure treatments of organophosphorus poisoning. J. Neurochem. 2017;142:26–40. doi: 10.1111/jnc.14026. PubMed DOI

Li C., Srivastava R.K., Athar M. Biological and environmental hazards associated with exposure to chemical warfare agents: Arsenicals. Ann. N. Y. Acad. Sci. 2016;1378:143–157. doi: 10.1111/nyas.13214. PubMed DOI PMC

Wilson C., Main M.J., Cooper N.J., Briggs M.E., Cooper A.I., Adams D.J. Swellable functional hypercrosslinked polymer networks for the uptake of chemical warfare agents. Polym. Chem. 2017;8:1914–1922. doi: 10.1039/C7PY00040E. DOI

Silva G.R., Borges I., Figueroa-Villar J.D., De Castro A.T. Defesa química: Histórico, classificação dos agentes de guerra e ação dos neurotóxicos. Quim. Nova. 2012;35:2083–2091. doi: 10.1590/S0100-40422012001000033. DOI

Worek F., Thiermann H., Szinicz L., Eyer P. Kinetic analysis of interactions between human acetylcholinesterase, structurally different organophosphorus compounds and oximes. Biochem. Pharmacol. 2004;68:2237–2248. doi: 10.1016/j.bcp.2004.07.038. PubMed DOI

Herbert J., Thiermann H., Worek F., Wille T. Precision cut lung slices as test system for candidate therapeutics in organophosphate poisoning. Toxicology. 2017;389:94–100. doi: 10.1016/j.tox.2017.07.011. PubMed DOI

Alencar Filho E.B., Santos A.A., Oliveira B.G. A quantum chemical study of molecular properties and QSPR modeling of oximes, amidoximes and hydroxamic acids with nucleophilic activity against toxic organophosphorus agents. J. Mol. Struct. 2017;1133:338–347. doi: 10.1016/j.molstruc.2016.12.035. DOI

Malfatti M.A., Enright H.A., Be N.A., Kuhn E.A., Hok S., McNerney M.W., Lao V., Nguyen T.H., Lightstone F.C., Carpenter T.S., et al. The biodistribution and pharmacokinetics of the oxime acetylcholinesterase reactivator RS194B in guinea pigs. Chem. Biol. Interact. 2017;277:159–167. doi: 10.1016/j.cbi.2017.09.016. PubMed DOI PMC

Kuča K., Kassa J. A comparison of the ability of a new bispyridinium oxime—1-(4-hydroxyiminomethylpyridinium)-4-(4-carbamoylpyridinium)butane dibromide and currently used oximes to reactivate nerve agent-inhibited rat brain acetylcholinesterase by in vitro methods. J. Enzym. Inhib. Med. Chem. 2003;18:529–535. doi: 10.1080/14756360310001605552. PubMed DOI

Delfino R.T., Ribeiro T.S., Figueroa-Villar J.D. Organophosphorus compounds as chemical warfare agents: A review. Sect. Title Toxicol. 2009;20:407–428. doi: 10.1590/S0103-50532009000300003. DOI

Quinn D.M. Acetylcholinesterase: Enzyme structure, reaction dynamics, and virtual transition states. Chem. Rev. 1987;87:955–979. doi: 10.1021/cr00081a005. DOI

Patrick G.L., Spencer J. An Introduction to Medicinal Chemistry. 4th ed. Oxford University Press; Oxford, UK: 2009.

Lemke T.L., David A. Williams Foye’s Principles of Medicinal Chemistry. 6th ed. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 2007.

Bergmann F., Wilson I.B., Nachmansohn D. Acetylcholinesterase. IX. Structural features determining the inhibition by amino acids and related compounds. J. Biol. Chem. 1950;186:693–703. PubMed

Wilson I.B., Bergmann F. Acetylcholinesterase. VIII. Dissociation constants of the active groups. J. Biol. Chem. 1950;186:683–692. PubMed

Wilson I.B., Bergmann F., Nachmansohn D. Acetylcholinesterase. X. Mechanism of the catalysis of acylation reactions. J. Biol. Chem. 1950;186:781–790. PubMed

Siegel G.J. Basic Neurochemistry: Molecular, Cellular, and Medical Aspects. 6th ed. Lippincott Williams & Wilkins; Philadelphia, PA, USA: 1999.

De Giacoppo J.O.S., De Lima W.E.A., Kuca K., Da Cunha E.F.F., França T.C.C., De Ramalho T.C. Guerra química: Perspectivas no estudo de reativadores da enzima acetilcolinesterase inibida por organofosforados. Rev. Virtual Quim. 2014;6:653–670.

Colovic M.B., Krstic D.Z., Lazarevic-Pasti T.D., Bondzic A.M., Vasic V.M. Acetylcholinesterase Inhibitors: Pharmacology and Toxicology. Curr. Neuropharmacol. 2013;11:315–335. doi: 10.2174/1570159X11311030006. PubMed DOI PMC

Kovarik Z., Bosak A., Latas T. Exploring the Active Sites of Cholinesterases by Inhibition with Bambuterol and Haloxon. Croat. Chem. Acta. 2003;76:63–67.

Saxena A., Redman A.M.G., Jiang X., Lockridge O., Doctor B.P. Differences in Active Site Gorge Dimensions of Cholinesterases Revealed by Binding of Inhibitors to Human Butyrylcholinesterase. Biochemistry. 1997;36:14642–14651. doi: 10.1021/bi971425+. PubMed DOI

Rosenberry T.L. Catalysis by acetylcholinesterase: Evidence that the rate-limiting step for acylation with certain substrates precedes general acid-base catalysis. Proc. Natl. Acad. Sci. USA. 1975;72:3834–3838. doi: 10.1073/pnas.72.10.3834. PubMed DOI PMC

Lockridge O. Genetic variants of human serum cholinesterase influence metabolism of the muscle relaxant succinylcholine. Pharmacol. Ther. 1990;47:35–60. doi: 10.1016/0163-7258(90)90044-3. PubMed DOI

Pezzementi L., Nachon F., Chatonnet A. Evolution of acetylcholinesterase and butyrylcholinesterase in the vertebrates: An atypical butyrylcholinesterase from the medaka oryzias latipes. PLoS ONE. 2011;6:17396. doi: 10.1371/annotation/938a4e59-a5d1-448c-b7c1-632bf9e7e8ef. PubMed DOI PMC

Ventura A.L.M., Abreu P.A., Freitas R.C.C., Sathler P.C., Loureiro N., Castro H.C. Colinergic system: Revisiting receptors, regulation and the relationship with Alzheimer disease, schizophrenia, epilepsy and smoking. Rev. Psiquiatr. Clin. 2010;37:74–80.

de Castro A.A., Prandi I.G., Kuca K., Ramalho T.C. Enzimas degradantes de organofosforados: Base molecular e perspectivas para biorremediação enzimática de agroquímicos. Ciência e Agrotecnologia. 2017;41:471–482. doi: 10.1590/1413-70542017415000417. DOI

Pereira A.F., de Castro A.A., Soares F.V., Soares Leal D.H., da Cunha E.F.F., Mancini D.T., Ramalho T.C. Development of technologies applied to the biodegradation of warfare nerve agents: Theoretical evidence for asymmetric homogeneous catalysis. Chem. Biol. Interact. 2019;308:323–331. doi: 10.1016/j.cbi.2019.06.007. PubMed DOI

de Castro A.A., Soares F.V., Pereira A.F., Silva T.C., Silva D.R., Mancini D.T., Caetano M.S., da Cunha E.F.F., Ramalho T.C. Asymmetric biodegradation of the nerve agents Sarin and VX by human dUTPase: Chemometrics, molecular docking and hybrid QM/MM calculations. J. Biomol. Struct. Dyn. 2019;37:2154–2164. doi: 10.1080/07391102.2018.1478751. PubMed DOI

Soares F.V., de Castro A.A., Pereira A.F., Leal D.H.S., Mancini D.T., Krejcar O., Ramalho T.C., da Cunha E.F.F., Kuca K. Theoretical Studies Applied to the Evaluation of the DFPase Bioremediation Potential against Chemical Warfare Agents Intoxication. Int. J. Mol. Sci. 2018;19:1257. doi: 10.3390/ijms19041257. PubMed DOI PMC

de Castro A.A., Assis L.C., Silva D.R., Corrêa S., Assis T.M., Gajo G.C., Soares F.V., Ramalho T.C. Computational enzymology for degradation of chemical warfare agents: Promising technologies for remediation processes. AIMS Microbiol. 2017;3:108–135. doi: 10.3934/microbiol.2017.1.108. PubMed DOI PMC

De Giacoppo J.O.S., França T.C.C., da Cunha E.F.F., Abagyan R., Mancini D.T., Ramalho T.C. Molecular modeling and in vitro reactivation study between the oxime BI-6 and acetylcholinesterase inhibited by different nerve agents. J. Biomol. Struct. Dyn. 2015;33:2048–2058. doi: 10.1080/07391102.2014.989408. PubMed DOI

Martins T.L.C., Ramalho T.C., Fiqueroa-Villar J.D. A Theoretical and Experimental 13C and 15N NMR Investigation of Guanylhydrazones in Solution. Mag. Reson. Chem. 2003;41:983–988. doi: 10.1002/mrc.1299. DOI

Ramalho T.C., de Castro A.A., Silva D.R., Silva M.C., Franca T.C.C., Bennion B.J., Kuca K. Computational Enzymology and Organophosphorus Degrading Enzymes: Promising Approaches Toward Remediation Technologies of Warfare Agents and Pesticides. Curr. Med. Chem. 2016;23:1041–1061. doi: 10.2174/0929867323666160222113504. PubMed DOI

Sharma R., Gupta B., Singh N., Acharya J.R., Musilek K., Kuca K., Ghosh K. Development and Structural Modifications of Cholinesterase Reactivators against Chemical Warfare Agents in Last Decade: A Review. Mini-Rev. Med. Chem. 2014;15:58–72. doi: 10.2174/1389557514666141128102837. PubMed DOI

Santos L.A., Prandi I.G., De Ramalho T.C. Could Quantum Mechanical Properties Be Reflected on Classical Molecular Dynamics? The Case of Halogenated Organic Compounds of Biological Interest. Front. Chem. 2019;7:848. doi: 10.3389/fchem.2019.00848. PubMed DOI PMC

Benschop H.P., De Jong L.P.A. Nerve Agent Stereoisomers: Analysis, Isolation, and Toxicology. Acc. Chem. Res. 1988;21:368–374. doi: 10.1021/ar00154a003. DOI

Melzer M., Chen J.C.H., Heidenreich A., Gäb J., Koller M., Kehe K., Blum M.M. Reversed enantioselectivity of diisopropyl fluorophosphatase against organophosphorus nerve agents by rational design. J. Am. Chem. Soc. 2009;131:17226–17232. doi: 10.1021/ja905444g. PubMed DOI

Marimuthu P., Lee Y.-J., Kim B., Seo S.S. In silico approaches to evaluate the molecular properties of organophosphate compounds to inhibit acetylcholinesterase activity in housefly. J. Biomol. Struct. Dyn. 2019;37:307–320. doi: 10.1080/07391102.2018.1426046. PubMed DOI

Wong P.T., Bhattacharjee S., Cannon J., Tang S., Yang K., Bowden S., Varnau V., O’Konek J.J., Choi S.K. Reactivity and mechanism of α-nucleophile scaffolds as catalytic organophosphate scavengers. Org. Biomol. Chem. 2019;17:3951–3963. doi: 10.1039/C9OB00503J. PubMed DOI

Quinn D.M., Topczewski J.J. Compounds and Methods to Treat Organophosphorus Poisoning. U.S. Patent 2016/151342 A1. 2016 Jun 2

Da Petronilho E.C., Figueroa-Villar J.D. Agents for defense against chemical warfare: Reactivators of the inhibited acetylcholinesterase with organophosphorus neurotoxic compounds. Rev. Virtual Quim. 2014;6:671–686. doi: 10.5935/1984-6835.20140042. DOI

Kim K., Tsay O.G., Atwood D.A., Churchill D.G. Destruction and Detection of Chemical Warfare Agents. Chem. Rev. 2011;111:5345–5403. doi: 10.1021/cr100193y. PubMed DOI

Ordentlich A., Barak D., Sod-Moriah G., Kaplan D., Mizrahi D., Segall Y., Kronman C., Karton Y., Lazar A., Marcus D., et al. Stereoselectivity toward VX is determined by interactions with residues of the acyl pocket as well as of the peripheral anionic site of AChE. Biochemistry. 2004;43:11255–11265. doi: 10.1021/bi0490946. PubMed DOI

Alvim R.S., Vaiss V.S., Leitão A.A., Borges I. Theoretical chemistry at the service of the chemical defense: Degradation of nerve agents in magnesium oxide and hydroxide surface. Rev. Virtual Quim. 2014;6:687–723. doi: 10.5935/1984-6835.20140043. DOI

Cavalcanti L.P.A.N., De Aguiar A.P., Lima J.A., Lima A.L.S. Organophosphorous poisoning: Treatment and analytical methodologies applied in evaluation of reactivation and inhibition of acetylcholinesterase. Rev. Virtual Quim. 2016;8:739–766. doi: 10.5935/1984-6835.20160056. DOI

Zilker T. Medical management of incidents with chemical warfare agents. Toxicology. 2005;214:221–231. doi: 10.1016/j.tox.2005.06.028. PubMed DOI

Dichtwald S., Weinbroum A.A. Bioterrorism and the anaesthesiologist’s perspective. Best Pract. Res. Clin. Anaesthesiol. 2008;22:477–502. doi: 10.1016/j.bpa.2008.05.004. PubMed DOI

Newman D.J., Cragg G.M. Natural products as sources of new drugs over the last 25 years. J. Nat. Prod. 2007;70:461–477. doi: 10.1021/np068054v. PubMed DOI

Wilson I.B. Acetylcholinesterase. XI. Reversibility of tetraethyl pyrophosphate. J. Biol. Chem. 1951;190:111–117. PubMed

Wilson I.B., Ginsburg S. A powerful reactivator of alkylphosphate-inhibited acetylcholinesterase. Biochim. Biophys. Acta. 1955;18:168–170. doi: 10.1016/0006-3002(55)90040-8. PubMed DOI

Petroianu G.A. The history of pyridinium oximes as nerve gas antidotes: The British contribution. Pharmazie. 2013;68:916–918. PubMed

Worek F., Thiermann H. The value of novel oximes for treatment of poisoning by organophosphorus compounds. Pharmacol. Ther. 2013;139:249–259. doi: 10.1016/j.pharmthera.2013.04.009. PubMed DOI

Franjesevic A.J., Sillart S.B., Beck J.M., Vyas S., Callam C.S., Hadad C.M. Resurrection and Reactivation of Acetylcholinesterase and Butyrylcholinesterase. Chemistry. 2019;25:5337–5371. doi: 10.1002/chem.201805075. PubMed DOI PMC

Wang J., Gu J., Leszczynski J., Feliks M., Sokalski W.A. Oxime-Induced Reactivation of Sarin-Inhibited AChE: A Theoretical Mechanisms Study. J. Phys. Chem. B. 2007;111:2404–2408. doi: 10.1021/jp067741s. PubMed DOI

Artursson E., Akfur C., Hörnberg A., Worek F., Ekström F. Reactivation of tabun-hAChE investigated by structurally analogous oximes and mutagenesis. Toxicology. 2009;265:108–114. doi: 10.1016/j.tox.2009.09.002. PubMed DOI

Kuca K., Jun D., Musilek K. Structural Requirements of Acetylcholinesterase Reactivators. Mini-Rev. Med. Chem. 2006;6:269–277. doi: 10.2174/138955706776073510. PubMed DOI

Lundy P.M., Raveh L., Amitai G. Development of the Bisquaternary Oxime HI-6 Toward Clinical Use in the Treatment of Organophosphate Nerve Agent Poisoning. Toxicol. Rev. 2006;25:231–243. doi: 10.2165/00139709-200625040-00004. PubMed DOI

Kitagawa D., Cavalcante S., de Paula R., Rodrigues R., Bernardo L., da Silva M., da Silva T., dos Santos W., Granjeiro J., de Almeida J., et al. In Vitro Evaluation of Neutral Aryloximes as Reactivators for Electrophorus eel Acetylcholinesterase Inhibited by Paraoxon. Biomolecules. 2019;9:583. doi: 10.3390/biom9100583. PubMed DOI PMC

Kuca K., Nepovimova E., Wu Q., de Souza F.R., de Castro Ramalho T., Franca T.C.C., Musilek K. Experimental hydrophilic reactivator: Bisoxime with three positive charges. Chem. Pap. 2019;73:777–782. doi: 10.1007/s11696-018-0612-6. DOI

Polisel D.A., de Castro A.A., Mancini D.T., da Cunha E.F.F., França T.C.C., Ramalho T.C., Kuca K. Slight difference in the isomeric oximes K206 and K203 makes huge difference for the reactivation of organophosphorus-inhibited AChE: Theoretical and experimental aspects. Chem. Biol. Interact. 2019;309:108671. doi: 10.1016/j.cbi.2019.05.037. PubMed DOI

Musilek K., Holas O., Kuca K., Jun D., Dohnal V., Opletalova V., Dolezal M. Synthesis of monooxime-monocarbamoyl bispyridinium compounds bearing (E)-but-2-ene linker and evaluation of their reactivation activity against tabun- and paraoxon-inhibited acetylcholinesterase. J. Enzyme Inhib. Med. Chem. 2008;23:70–76. doi: 10.1080/14756360701383981. PubMed DOI

Kuca K., Musilek K., Jun D., Zdarova-Karasova J., Nepovimova E., Soukup O., Hrabinova M., Mikler J., Franca T.C.C., Da Cunha E.F.F., et al. A newly developed oxime K203 is the most effective reactivator of tabun-inhibited acetylcholinesterase. BMC Pharmacol. Toxicol. 2018;19:1–10. doi: 10.1186/s40360-018-0196-3. PubMed DOI PMC

Lorke D.E., Nurulain S.M., Hasan M.Y., Kuča K., Petroianu G.A. Oximes as pretreatment before acute exposure to paraoxon. J. Appl. Toxicol. 2019;39:1506–1515. doi: 10.1002/jat.3835. PubMed DOI

Jaćević V., Nepovimova E., Kuča K. Toxic Injury to Muscle Tissue of Rats Following Acute Oximes Exposure. Sci. Rep. 2019;9:1–13. doi: 10.1038/s41598-018-37837-4. PubMed DOI PMC

Jaćević V., Nepovimova E., Kuča K. Acute Toxic Injuries of Rat’s Visceral Tissues Induced by Different Oximes. Sci. Rep. 2019;9:1–13. doi: 10.1038/s41598-019-52768-4. PubMed DOI PMC

Katz F.S., Pecic S., Tran T.H., Trakht I., Schneider L., Zhu Z., Ton-That L., Luzac M., Zlatanic V., Damera S., et al. Discovery of New Classes of Compounds that Reactivate Acetylcholinesterase Inhibited by Organophosphates. ChemBioChem. 2015;16:2205–2215. doi: 10.1002/cbic.201500348. PubMed DOI PMC

de Koning M.C., Horn G., Worek F., van Grol M. Discovery of a potent non-oxime reactivator of nerve agent inhibited human acetylcholinesterase. Eur. J. Med. Chem. 2018;157:151–160. doi: 10.1016/j.ejmech.2018.08.016. PubMed DOI

Cadieux C.L., Wang H., Zhang Y., Koenig J.A., Shih T.M., McDonough J., Koh J., Cerasoli D. Probing the activity of a non-oxime reactivator for acetylcholinesterase inhibited by organophosphorus nerve agents. Chem. Biol. Interact. 2016;259:133–141. doi: 10.1016/j.cbi.2016.04.002. PubMed DOI PMC

Niessen K.V., Seeger T., Rappenglück S., Wein T., Höfner G., Wanner K.T., Thiermann H., Worek F. In vitro pharmacological characterization of the bispyridinium non-oxime compound MB327 and its 2- and 3-regioisomers. Toxicol. Lett. 2018;293:190–197. doi: 10.1016/j.toxlet.2017.10.009. PubMed DOI

Zhuang Q., Franjesevic A.J., Corrigan T.S., Coldren W.H., Dicken R., Sillart S., DeYong A., Yoshino N., Smith J., Fabry S., et al. Demonstration of In Vitro Resurrection of Aged Acetylcholinesterase after Exposure to Organophosphorus Chemical Nerve Agents. J. Med. Chem. 2018;61:7034–7042. doi: 10.1021/acs.jmedchem.7b01620. PubMed DOI

Gorecki L., Korabecny J., Musilek K., Malinak D., Nepovimova E., Dolezal R., Jun D., Soukup O., Kuca K. SAR study to find optimal cholinesterase reactivator against organophosphorous nerve agents and pesticides. Arch. Toxicol. 2016;90:2831–2859. doi: 10.1007/s00204-016-1827-3. PubMed DOI

Worek F., Thiermann H., Wille T. Oximes in organophosphate poisoning: 60 years of hope and despair. Chem. Biol. Interact. 2016;259:93–98. doi: 10.1016/j.cbi.2016.04.032. PubMed DOI

Kovalevsky A., Blumenthal D.K., Cheng X., Taylor P., Radić Z. Limitations in current acetylcholinesterase structure–based design of oxime antidotes for organophosphate poisoning. Ann. N. Y. Acad. Sci. 2016;1378:41–49. doi: 10.1111/nyas.13128. PubMed DOI PMC

Carletti E., Colletier J.-P., Dupeux F., Trovaslet M., Masson P., Nachon F. Structural Evidence That Human Acetylcholinesterase Inhibited by Tabun Ages through O-Dealkylation. J. Med. Chem. 2010;53:4002–4008. doi: 10.1021/jm901853b. PubMed DOI

Kalisiak J., Ralph E.C., Zhang J., Cashman J.R. Amidine−Oximes: Reactivators for Organophosphate Exposure. J. Med. Chem. 2011;54:3319–3330. doi: 10.1021/jm200054r. PubMed DOI

Quinn M.D., Topczewski J., Yasapala N., Lodge A. Why is Aged Acetylcholinesterase So Difficult to Reactivate? Molecules. 2017;22:1464. doi: 10.3390/molecules22091464. PubMed DOI PMC

Chambers J.E., Chambers H.W., Meek E.C. Novel Oximes for Reactivating Butyrylcholinesterase. 2017/0258774 A1. U.S. Patent. 2017 Sep 14;

Chambers J.E., Meek E.C., Bennett J.P., Bennett W.S., Chambers H.W., Leach C.A., Pringle R.B., Wills R.W. Novel substituted phenoxyalkyl pyridinium oximes enhance survival and attenuate seizure-like behavior of rats receiving lethal levels of nerve agent surrogates. Toxicology. 2016;339:51–57. doi: 10.1016/j.tox.2015.12.001. PubMed DOI PMC

Kovarik Z., Ciban N., Radić Z., Simeon-Rudolf V., Taylor P. Active site mutant acetylcholinesterase interactions with 2-PAM, HI-6, and DDVP. Biochem. Biophys. Res. Commun. 2006;342:973–978. doi: 10.1016/j.bbrc.2006.02.056. PubMed DOI

Musilova L., Kuca K., Jung Y.-S., Jun D. In vitro oxime-assisted reactivation of paraoxon-inhibited human acetylcholinesterase and butyrylcholinesterase. Clin. Toxicol. 2009;47:545–550. doi: 10.1080/15563650903058914. PubMed DOI

Jun D., Musilova L., Pohanka M., Jung Y.-S., Bostik P., Kuca K. Reactivation of Human Acetylcholinesterase and Butyrylcholinesterase Inhibited by Leptophos-Oxon with Different Oxime Reactivators in Vitro. Int. J. Mol. Sci. 2010;11:2856–2863. doi: 10.3390/ijms11082856. PubMed DOI PMC

Jun D., Musilova L., Musilek K., Kuca K. In Vitro Ability of Currently Available Oximes to Reactivate Organophosphate Pesticide-Inhibited Human Acetylcholinesterase and Butyrylcholinesterase. Int. J. Mol. Sci. 2011;12:2077–2087. doi: 10.3390/ijms12032077. PubMed DOI PMC

Valdez C.A., Be N.A., Alfatti M.A., Enright H.A., Bennion B.J., Carpenter T.S., Hok S., lao H.L., Nguyen T.H. Compounds for Central Reactivation of Organophosphorus-Based Compound-Inhibited Acetylcolinesterase and/or Inactivation of Organophosphorus-Based Acetylcholinesterase Inhibitors and Related Compositions Methods and Systems for Making and Using Them. 2019/0152920 A1. U.S. Patent. 2019 May 23;

Batool A., Kamal M.A., Rizvi S.M.D., Rashid S. Topical Discoveries on Multi-Target Approach to Manage Alzheimer’s Disease. Curr. Drug Metab. 2018;19:704–713. doi: 10.2174/1389200219666180305152553. PubMed DOI

Du W.-J., Guo J.-J., Gao M.-T., Hu S.-Q., Dong X.-Y., Han Y.-F., Liu F.-F., Jiang S., Sun Y. Brazilin inhibits amyloid β-protein fibrillogenesis, remodels amyloid fibrils and reduces amyloid cytotoxicity. Sci. Rep. 2015;5:7992. doi: 10.1038/srep07992. PubMed DOI PMC

Khavrutskii I., Wallqvist A. Compositions and Methods for Reactivating Cholinesterases. 2017/218886 A1. WO Patent. 2017 Dec 21;

Hardman J.G., Limbird L.E., Gilman A.G. Goodman & Gilman’s The Pharmacological Basis of Therapeutics. 10th ed. McGraw-Hill; New York, NY, USA: 2001.

Gorecki L., Korabecny J., Musilek K., Nepovimova E., Malinak D., Kucera T., Dolezal R., Jun D., Soukup O., Kuca K. Progress in acetylcholinesterase reactivators and in the treatment of organophosphorus intoxication: A patent review (2006–2016) Expert Opin. Ther. Pat. 2017;27:971–985. doi: 10.1080/13543776.2017.1338275. PubMed DOI

Atomistic Origins of Resurrection of Aged Acetylcholinesterase by Quinone Methide Precursors

Charged pyridinium oximes with thiocarboxamide moiety are equally or less effective reactivators of organophosphate-inhibited cholinesterases compared to analogous carboxamides

Understanding the Interaction Modes and Reactivity of Trimedoxime toward MmAChE Inhibited by Nerve Agents: Theoretical and Experimental Aspects